Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


eISSN: 1643-3750

Sex Differences in Presentation, Quality of Life, and Treatment in Chinese Atrial Fibrillation Patients: Insights from the China Atrial Fibrillation Registry Study

Yan-Ming Li, Chao Jiang, Liu He, Xin-Xu Li, Xiao-Xia Hou, San-Shuai Chang, Gregory Y.H. Lip, Xin Du, Jian-Zeng Dong, Chang-Sheng Ma

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Centre for Cardiovascular Diseases, Beijing, China (mainland)

Med Sci Monit 2019; 25:8011-8018

DOI: 10.12659/MSM.919366

Available online: 2019-10-25

Published: 2019-10-25


BACKGROUND: There is a growing recognition of sex-related disparities in atrial fibrillation (AF). However, limited data is available in Chinese AF patients.
MATERIAL AND METHODS: We compared symptoms, quality of life (QoL), and treatment of AF according to sex from the China AF Registry study.
RESULTS: We studied 14 723 patients with non-valvular AF, of whom 5645 patients (38.3%) were female. Women were older than men (67.5±10.6 vs. 62.2±12.2). Compared to men, women had more comorbidities and a higher proportion of CHA₂DS₂-VASC score ≥2. Women with AF experienced more severe or disabling symptoms than men (33.7% vs. 22.9% in age <75 group; 40.3% vs. 28.7% in age ≥75 group; both P<0.0001). After multivariate analysis, women with AF still had lower QoL (OR 0.69; 95%CI, 0.63-0.76; P<0.0001). Women tended to have lower rates of ablation and rhythm-control drug use in those aged <75 years. Oral anticoagulant use was low and had no sex difference in AF patients with a CHA₂DS₂-VASC score ≥2.
CONCLUSIONS: In Chinese AF patients, women were older and more symptomatic, and had worse QoL. Despite all these differences, women tended to receive less rhythm-control treatment in those aged <75 years. Oral anticoagulant was substantially underused in high stroke risk patients, regardless of sex.

Keywords: Atrial Fibrillation, Quality of Life, Sex Characteristics, Therapeutics